FDA Approves MYCOPHENOLATE MOFETIL — Ascend Laboratories, LLC

Ascend Laboratories, LLC received final approval on November 14, 2014, for its Abbreviated New Drug Application (ANDA) 203005 for Mycophenolate Mofetil Oral Suspension, an authorized generic. This approval intensifies price competition in the anti-rejection therapy market and allows the company to capitalize on the accessibility provided by the patented oral suspension formulation.